SLC5A2 and heart failure: Given the recent publication of the data from the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial (18), which was a large randomized double-blind trial that compared the effect of dapagliflozin versus placebo in patients with HFmrEF or HFpEF, an updated meta-analysis that focuses on the effect of SGLT2 inhibitor in patients with HFmrEF or HFpEF is urgently needed.